20 years ago, stem cell physicians were nearly nonexistent. Ten years ago, only a small number offered a limited range of procedures. Today, hundreds of physicians provide stem cell treatments, including injections and infusions.

To date, the U.S. FDA has approved 43 cell and gene therapy products, eight of which are umbilical cord blood derivatives. These include ALLOCORD, CLEVECORD, HEMACORD, and Ducord, as well as four hematopoietic progenitor cell (HPC) products developed by Clinimmune Labs, MD Anderson Cord Blood Bank, LifeSouth Community Blood Centers, and Bloodworks.

As the FDA states, “The only stem cell-based products that are FDA-approved for use in the U.S. consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood. These products are approved for limited use in patients with disorders affecting the blood production system.”

The U.S. FDA has also approved a number of CAR-T cell therapies (7), as well as 15 gene therapies that are not CAR-T cell therapies and 12 cell therapies that are not cord blood derived therapeutics.

Beyond these FDA-approved treatments, a wide range of stem cell therapies are now available directly to patients.

A Rapidly Expanding Market

Over the past decade, the number of physicians offering stem cell treatments has grown exponentially. These therapies involve stem cells derived from various sources, including:

• Bone marrow
• Adipose tissue
• Peripheral blood
• Umbilical cord blood and tissue
• Placental blood and tissue
• Amniotic fluid and tissue

Currently, over 425 medical clinics provide stem cell services directly to patients.

Due to the rapid growth of this sector, many clients have requested a comprehensive, searchable, and sortable database of stem cell treatment providers. In response, we have undertaken this task to streamline access to critical provider information.